Technical Analysis for ATRA - Atara Biotherapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | -3.86% | |
Wide Bands | Range Expansion | -3.86% | |
Up 3 Days in a Row | Strength | -3.86% | |
Lower Bollinger Band Walk | Weakness | 1.70% | |
Wide Bands | Range Expansion | 1.70% | |
Oversold Stochastic | Weakness | 1.70% | |
Hammer Candlestick | Bullish | 10.59% | |
Stochastic Buy Signal | Bullish | 10.59% | |
Pocket Pivot | Bullish Swing Setup | 10.59% | |
Lower Bollinger Band Walk | Weakness | 10.59% |
Alert | Time |
---|---|
Down 5% | 14 minutes ago |
20 DMA Resistance | 33 minutes ago |
Down 3% | 33 minutes ago |
Up 3% | 33 minutes ago |
Down 2 % | 33 minutes ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/10/2024
Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 2.535 |
52 Week Low | 0.1986 |
Average Volume | 1,575,656 |
200-Day Moving Average | 0.99 |
50-Day Moving Average | 0.68 |
20-Day Moving Average | 0.65 |
10-Day Moving Average | 0.60 |
Average True Range | 0.07 |
RSI (14) | 48.98 |
ADX | 17.2 |
+DI | 24.16 |
-DI | 22.48 |
Chandelier Exit (Long, 3 ATRs) | 0.56 |
Chandelier Exit (Short, 3 ATRs) | 0.68 |
Upper Bollinger Bands | 0.77 |
Lower Bollinger Band | 0.53 |
Percent B (%b) | 0.47 |
BandWidth | 36.58 |
MACD Line | -0.03 |
MACD Signal Line | -0.03 |
MACD Histogram | -0.0039 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.75 | ||||
Resistance 3 (R3) | 0.74 | 0.71 | 0.73 | ||
Resistance 2 (R2) | 0.71 | 0.68 | 0.71 | 0.72 | |
Resistance 1 (R1) | 0.67 | 0.66 | 0.69 | 0.68 | 0.72 |
Pivot Point | 0.64 | 0.64 | 0.65 | 0.64 | 0.64 |
Support 1 (S1) | 0.60 | 0.61 | 0.62 | 0.61 | 0.56 |
Support 2 (S2) | 0.57 | 0.59 | 0.57 | 0.56 | |
Support 3 (S3) | 0.53 | 0.57 | 0.55 | ||
Support 4 (S4) | 0.54 |